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Protein S (PS), mainly synthesized in hepatocytes and endothelial cells, plays a critical role as a cofactor of anticoagulant activated
protein C (APC). PS activity is regulated by C4b-binding protein (C4BP), structurally composed of seven α-chains (C4BPα) and a
β-chain(C4BPβ).Inthispaper,basedprimarilyonourpreviousstudies,wereviewthelipopolysaccharide(LPS)-inducedsignaling
which aﬀects expression of PS and C4BP in the liver. Our in vivo studies in rats showed that after LPS injection, plasma PS levels
are signiﬁcantly decreased, whereas plasma C4BP levels ﬁrst are transiently decreased after 2 to 12 hours and then signiﬁcantly
increased after 24 hours. LPS decreases PS antigen and mRNA levels in both hepatocytes and sinusoidal endothelial cells (SECs),
and decreases C4BP antigen and both C4BPα and C4BPβ mRNA levels in hepatocytes. Antirat CD14 and antirat Toll-like receptor
(TLR)-4 antibodies inhibited LPS-induced NFκB activation in both hepatocytes and SECs. Furthermore, inhibitors of NFκBa n d
MEK recovered the LPS-induced decreased expression of PS in both cell types and the LPS-induced decreased expression of C4BP
in hepatocytes. These data suggest that the LPS-induced decrease in PS expression in hepatocytes and SECs and LPS-induced
decrease in C4BP expression in hepatocytes are mediated by MEK/ERK signaling and NFκB activation and that membrane-bound
CD14 and TLR-4 are involved in this mechanism.
1.Introduction
Protein S (PS), a vitamin K-dependent plasma glycoprotein
(Mr 75,000), is a physiologically important regulator of
blood coagulation, as patients with hereditary PS deﬁciency
have severe thrombotic diseases [1–3]. In the blood coagu-
lation system, PS is a cofactor of activated protein C (APC),
which inactivates the blood coagulation factor Va and factor
VIIIa [4–6]( Figure 1). PS may also directly inhibit the
prothrombinase complex by binding to factor Va and factor
Xa [7, 8]. In human plasma, PS circulates in free form and
in complex with C4b-binding protein (C4BP), a protein of
the classical complement pathway [9, 10]. C4BP consists of
seven α chains (Mr 70,000) and a β chain (Mr 45,000), with
the β chain being important in complex formation with PS
[11–13]. Both forms of PS are capable of binding to APC,
but only the free form acts as a cofactor [14, 15]( Figure 2).
Additionally, PS may promote phagocytosis of apoptotic
cells by macrophages [16] and mediate neuroprotection via
APC [17]. These observations suggest that PS has important
functions in both blood coagulation and inﬂammation.
Human PS is mainly synthesized in hepatocytes,
endothelial cells and megakaryocytes [18–20], and C4BP in
hepatocytes [21]. Acquired decreased plasma PS levels have
been associated with liver diseases [22], pregnancy [23],
oral contraceptive use [24], sepsis-associated disseminated
intravascular coagulation (DIC) [25], and systemic lupus
erythematosus [26], and patients with these conditions have
anincreasedincidenceofthromboticevents.Decreasedlevels
of free PS may also lead to thrombotic tendency; therefore, it
is believed that increased levels of plasma C4BP, as found in
type III PS deﬁciency, are a risk factor of thrombosis [27].
Previously, we demonstrated that PS acts as a cofactor
for APC in rats, and that it forms a complex with rat C4BP,
as in humans [28]. Studies in various species demonstrated
that both humans and rats have the PS-C4BP complex in2 Gastroenterology Research and Practice
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Figure 1: Blood coagulation pathway and protein C anticoagulant pathway. Thrombin, bound to thrombomodulin (TM), activates protein
C which binds to endothelial protein C receptor (EPCR). Activated protein C (APC) inactivates coagulation factor Va (Va) and factor VIIIa
(VIIIa) in the presence of protein S (PS). PS circulates in free form and in complex with C4b-binding protein (C4BP) in plasma, and the free
form of PS plays a role as a cofactor of APC. TF: Tissue factor, PL: Phospholipids.
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Figure 2: Functions of PS and PS-C4BP complex. PS circulates in free form (about 40%) and in complex form with C4BP (about 60%) in
plasma. C4BP is comprised of seven α chains and a β chain, and PS binds to the β chain. APC proteolytically converts factors Va and VIIIa
(Va/VIIIa) into inactivated factors Va and VIIIa (Vi/VIIIi) in the presence of free form PS, but not the complex form PS with C4BP.
plasma [10, 14, 28, 29]; therefore, rats are considered to be
the most appropriate animal to study the pathophysiological
role of PS. In this paper, we describe changes in the plasma
levels of PS and C4BP. We also evaluate the in vitro eﬀect
of LPS on PS and C4BP expression in hepatocytes and/or
sinusoidal endothelial cells (SECs) isolated from rats and the
LPS-mediated signaling that aﬀects PS and C4BP expression
in these cells.
2. Effect of LPS on PS Expression
In Vivo and In Vitro
We showed that in a rat endotoxemia model [30, 31],
prepared by intraperitoneal injection of LPS, the total PS
level in plasma was signiﬁcantly decreased while the free PS
level was markedly decreased in plasma after LPS injection
(Figures 3(a) and 3(b)). APC cofactor activity of plasma
isolated from rats 24 hours after LPS injection was also
evaluated by activated partial thromboplastin time (APTT),
suggesting that plasma obtained from rats 24 hours after
LPS injection prolonged the APTT signiﬁcantly less than
plasma from nontreated rats (data not shown). These results
suggest that LPS-induced reduction of plasma PS is a cause
of thrombotic tendency in patients with sepsis. Thses results
were consistent with the report by Hesselvik et al. that
patients with sepsis have decreased plasma levels of PS, and
that this is associated with thrombotic events [32]. In the
liver, PS mRNA transiently decreased from 4 hours to 8
hours after LPS treatment and then returned to baseline
levels; however, the plasma antigen level of PS did not
recover concomitantly with the PS mRNA expression [30].
The detailed mechanism of this phenomenon is unclear, thusGastroenterology Research and Practice 3
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Figure 3: Changes in plasma levels of total PS and free PS in LPS-treated rats. Citrated plasma was obtained from three rats treated with LPS
intraperitoneally (2mg · kg
−1) at each time point to determine (a) plasma total PS antigen levels and (b) plasma free PS antigen levels, as
described previously in [31]. Data are expressed as the mean ± S.D. (n = 3). ∗P<. 05 versus time 0.
future investigations are needed. The in vitro studies using
hepatocytes and SECs isolated from normal rats indicated
that LPS dose-dependently decreased mRNA expression
of PS in both cells, and these decreases occurred at the
transcriptional level [30]. These data suggest that decreased
plasma level of PS in LPS-treated rats is mainly due to
reduced PS mRNA expression in both hepatocytes and SECs.
3. Effect of LPS on C4BP Expression
In Vivo and In Vitro
It is reported that plasma C4BP levels are signiﬁcantly
increased in patients with severe infection and septic shock
[32], but it is unknown whether C4BP expression in the
liver is directly aﬀected by LPS. We examined the eﬀect
of LPS on C4BP expression in vivo in the liver of rats
and in vitro in isolated rat hepatocytes. We observed that
LPS transiently decreased the plasma level of C4BP antigen
with a maximum decrease between 4 hours and 6 hours,
followed by a signiﬁcant increase by 24 hours after LPS
injection (Figure 4(a))[ 31]. This result was consistent with
the data that free PS was signiﬁcantly decreased for 24
hours after LPS injection (Figure 3(b)). However, the PS-
C4BP complex level was not signiﬁcantly changed within
24 hours after LPS injection (Figure 4(b)). The in vitro
studiesusinghepatocytesisolatedfromnormalratsindicated
that LPS directly decreased both C4BPα and C4BPβ mRNA
expression in hepatocytes [31]. These data suggest that the
early decrease of plasma C4BP is caused by a direct eﬀect
of LPS. It is also reported that interleukin (IL)-6 increased
C4BP expression in HepG2 cells [33],suggestingthat in LPS-
treated rats the relatively late increase in the plasma level of
C4BP is caused by IL-6. It is reported that IL-6 also increased
PS expression in HepG2 cells [34] and in rat hepatocytes
[30]. However, it is unclear whether IL-6 is one of the causes
of thrombotic tendency. To clarify this point we prepared
IL-6-injected rats, and in vivo eﬀect of IL-6 on plasma PS,
C4BP and PS-C4BP complex level was examined. Our data
indicated that both C4BP and PS-C4BP complex levels in
plasma are increased until 8 hours after IL-6 injection, and
then gradually decreased, and free PS level is decreased 24
hours after IL-6 injection, so that APC cofactor activity of
plasma24hoursafterIL-6injectionisdecreasedascompared
with nontreated rats (data not shown). These results suggest
that IL-6 causes thrombotic tendency by increasing C4BP
expression in hepatocytes followed by increasing plasma
PS-C4BP complex and decreasing plasma free PS level.
These results also suggest that IL-6-induced reduction of
free plasma PS is also the cause of thrombotic tendency in
endotoxemia rats, and the major eﬀect of IL-6 is increasing
of C4BP expression in hepatocyte rather than increasing of
PS expression in hepatocytes and SECs.
4. Signal Transduction Pathway Involved in
LPS-InducedExpressionofPSinHepatocytes
andSECsandC4BP inHepatocytes
CD14 and TLR-4 are necessary for signal transduction
induced by LPS in which LPS, bound to CD14, can interact
with TLR-4 in the presence of myeloid diﬀerentiation
protein-2 (MD-2) [35, 36]. It is known that induction by
LPS on NFκB activation occurs via CD14 and TLR-4 in
human endothelial cells [37], and mouse hepatocytes [38].
Recently, we showed that rat hepatocytes and SECs also4 Gastroenterology Research and Practice
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Figure 4: Changes in plasma levels of C4BP and PS-C4BP complex in LPS-treated rats. Citrated plasma was obtained from three rats treated
with LPS intraperitoneally (2mg · kg
−1) at each time point to determine (a) plasma C4BP antigen levels and (b) plasma PS-C4BP complex
antigen levels, as described previously in [31]. Data are expressed as the mean ± S.D. (n = 3). ∗P<. 05 versus time 0.
Down-regulation of PS and C4BP gene expression
NFκB
IκB
TLR-4
LPS
CD14
MD-2
TLR-4
MEK
Extracellular
Cytoplasm
Nucleus
LPS
MD-2
NFκB
CD14
Figure 5: Mechanism of LPS-induced decreased expression of PS and C4BP in hepatocytes. LPS binds to membrane-bound CD14 and TLR-4,
followed by activation of MEK/ERK and NFκB. Activated NFκB interacts with the promoter regions of the PS and C4BPα and C4BPβ genes,
leading to decreased PS expression in hepatocytes and SECs, and decreased C4BP expression in hepatocytes.
express CD14 and TLR-4 [30]. Further, gel mobility-shift
assay indicated that anti-CD14 and anti-TLR-4 antibodies
inhibit LPS-induced NFκBa c t i v a t i o ni nb o t hh e p a t o c y t e s
and SECs. These results suggest that LPS also induced NFκB
activation via CD14 and TLR-4 in both rat hepatocytes and
SECs [30].
Furthermore, we found that a NFκB inhibitor blocked
LPS-induced decreased expression of PS in both hepatocytes
and SECs and the LPS-induced decreased C4BPβ expression
in hepatocytes [30, 31], suggesting that NFκBa c t i v a t i o ni s
involved in the expression of PS and C4BP in hepatocytes
and/or endothelial cells. These data also suggest that the
rat PS, C4BPα and C4BPβ gene promoters contain a NFκB
consensus sequence. In addition, we found that a MEK
inhibitor blocks LPS-induced reduction of PS expression
in hepatocytes and SECs, and LPS-induced reduction of
C4BP in hepatocytes [30, 31]. These data are consistent
with previous studies [36, 37], that LPS induces activationGastroenterology Research and Practice 5
of the MEK/ERK pathway and NFκB nuclear translocation
in hepatocytes and endothelial cells. These ﬁndings suggest
that NFκB activation and MEK/ERK pathway, but not the
protein kinase C, JNK and p38 MAPK pathways, are linked
to LPS-induced decreased PS expression in rat hepatocytes
and SECs, and also linked to LPS-induced decreased C4BP
expression in rat hepatocytes (Figure 5).
5. Effect of Inﬂammatory Cytokineson PS and
C4BP ExpressioninHepatocytesandSECs
LPS stimulates monocytes and endothelial cells to express
various inﬂammatory cytokines [39, 40]. Among these
inﬂammatory cytokines, tumor necrosis factor-alpha (TNF-
α) decreased PS expression in rat SECs [30], and IL-
6 increased PS expression and C4BPβ expression, but
not C4BPα expression, in rat hepatocytes [30, 31]. On
the other hand, LPS directly decreased PS expression in
human umbilical vein endothelial cells (HUVECs) (our
unpublished observations). These ﬁndings are consistent
with previous reports showing that TNF-α decreases PS
expression in HUVECs [41] and that IL-6 increases PS
expression in human hepatoma cell lines [34]. As described
above plasma PS antigen and activity are decreased in LPS-
treated rats, and this suggests that both LPS and TNF-α
induce decreased plasma PS levels, which causes thrombotic
tendency in patients with sepsis. On the other hand IL-6
increasedPSexpressioninhepatocytes,butthisIL-6-induced
increase of PS expression is not enough to compensate
for LPS- and TNF-α-induced decreased expression of PS
in hepatocytes and/or endothelial cells. Furthermore, IL-
6 itself increased C4BP expression in rat hepatocytes, and
the resulting decrease of free PS in plasma is thought to
be the cause of thrombotic tendency. Overall, these results
suggest that various cytokines which are induced by LPS
in monocytes and endothelial cells induced thrombotic
tendency in patients with sepsis. Recently, it was reported
that IL-6-induced increased PS expression in HepG2 cells
is regulated through the signal transducer and activator of
transcription(STAT3)bindingsite,whichislocatedinthe5 -
ﬂanking region of the human PS gene [42]. The mechanisms
by which TNF-α speciﬁcally decreases PS expression in
SECs and IL-6 speciﬁcally increases C4BPβ expression in
hepatocytes are unknown. Further investigations are needed
to elucidate the signal transduction pathway for IL-6 and
TNF-α action in hepatocytes and SECs.
6. Conclusion
LPSdirectlydecreasesPSexpressioninhepatocytesandSECs
and decreases C4BP expression in hepatocytes. Membrane-
bound CD14 and TLR-4 mediate the LPS-induced activation
of MEK/ERK and NFκB and the activated NFκB interacts
with promoter regions of the PS and C4BPα and C4BPβ
genes. Moreover, LPS activates TLR-4 in monocytes to
express IL-6 which stimulates expression of PS and C4BP
in hepatocytes and/or endothelial cells. Our ﬁndings may
be useful for the development of anticoagulation therapy
involving PS and C4BP to regulate LPS-TLR-4-mediated
activation of the NFκBa n dM E Ks y s t e m .
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